These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 25895921)

  • 1. Pembrolizumab superior to ipilimumab in melanoma.
    Cancer Discov; 2015 Jun; 5(6):568. PubMed ID: 25895921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
    Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
    N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab use for the treatment of advanced melanoma.
    Specenier P
    Expert Opin Biol Ther; 2017 Jun; 17(6):765-780. PubMed ID: 28323504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma.
    Sullivan RJ; Flaherty KT
    Clin Cancer Res; 2015 Jul; 21(13):2892-7. PubMed ID: 25931451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Pembrolizumab for Advanced Melanoma Treatment in Portugal.
    Miguel LS; Lopes FV; Pinheiro B; Wang J; Xu R; Pellissier J; Laires PA
    Value Health; 2017 Sep; 20(8):1065-1073. PubMed ID: 28964438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-FDG PET/CT Reveals Disease Remission in a Patient With Ipilimumab-Refractory Advanced Melanoma Treated With Pembrolizumab.
    Sachpekidis C; Hassel JC; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2016 Feb; 41(2):156-8. PubMed ID: 26545022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 9. Pembrolizumab: A Review in Advanced Melanoma.
    Deeks ED
    Drugs; 2016 Mar; 76(3):375-86. PubMed ID: 26846323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab for patients with advanced melanoma.
    Burki TK
    Lancet Oncol; 2015 Jun; 16(6):e264. PubMed ID: 25921425
    [No Abstract]   [Full Text] [Related]  

  • 11. [Not Available].
    Pagès C; Baroudjian B; Lebbé C
    Bull Cancer; 2016 Nov; 103 Suppl 1():S132-S137. PubMed ID: 28057176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of metastatic mucosal melanoma to immunotherapy: It can get worse before it gets better.
    Atrash S; Makhoul I; Mizell JS; Hutchins L; Mahmoud F
    J Oncol Pharm Pract; 2017 Apr; 23(3):215-219. PubMed ID: 26811403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma.
    Faghfuri E; Faramarzi MA; Nikfar S; Abdollahi M
    Expert Rev Anticancer Ther; 2015; 15(9):981-93. PubMed ID: 26313415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
    Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
    Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined low-dose ipilimumab and pembrolizumab after sequential ipilimumab and pembrolizumab failure in advanced melanoma.
    Kirchberger MC; Hauschild A; Schuler G; Heinzerling L
    Eur J Cancer; 2016 Sep; 65():182-4. PubMed ID: 27501507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab's non-cross resistance mechanism of action successfully overthrown ipilimumab.
    Wahid M; Akhter N; Jawed A; Dar SA; Mandal RK; Lohani M; Areeshi MY; Khan S; Haque S
    Crit Rev Oncol Hematol; 2017 Mar; 111():1-6. PubMed ID: 28259284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy in advanced melanoma: a network meta-analysis.
    Pyo JS; Kang G
    Immunotherapy; 2017 May; 9(6):471-479. PubMed ID: 28472905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.
    Hersey P; Gowrishankar K
    Future Oncol; 2015; 11(1):133-40. PubMed ID: 25572788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma.
    Sullivan RJ; Flaherty KT
    Nat Rev Clin Oncol; 2015 Nov; 12(11):625-6. PubMed ID: 26416151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.